Of course, the success of the Express² stent system has a profound relevance for our TAXUS™ paclitaxel-eluting coronary stent system, which is built on the Express stent technology. The conformability of our stent within a diseased coronary artery is extremely beneficial to our drug-eluting technology and has contributed to the clinical differentiation of our drug-eluting stent platform from others.